Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biogen Inc (BIIB)

270.28   -3.56 (-1.3%) 01-21 01:08
Open: 274.31 Pre. Close: 273.84
High: 274.54 Low: 267.665
Volume: 1,293,364 Market Cap: 41,591M
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 274.842 - 277.081 277.081 - 278.584
Low: 263.031 - 265.498 265.498 - 267.153
Close: 267.045 - 270.872 270.872 - 273.442

Technical analysis

as of: 2021-01-20 4:44:56 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 330.08     One year: 385.53
Support: Support1: 255.28    Support2: 238.40
Resistance: Resistance1: 282.60    Resistance2: 330.08
Pivot: 258.25
Moving Average: MA(5): 273.38     MA(20): 255.71
MA(100): 263.54     MA(250): 283.84
MACD: MACD(12,26): 6.61     Signal(9): 3.88
Stochastic oscillator: %K(14,3): 79.00     %D(3): 84.65
RSI: RSI(14): 62.45
52-week: High: 374.99  Low: 223.25  Change(%): -4.9
Average Vol(K): 3-Month: 177001  10-Days: 141797

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
BIIB has closed below upper band by 27.2%. Bollinger Bands are 24.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 14 Jan 2021
Biogen Stock Jumps Amid Signs Alzheimer’s Drug Discussions With FDA Continue - Barron's

Thu, 14 Jan 2021
Do Institutions Own Biogen Inc. (NASDAQ:BIIB) Shares? - Simply Wall St

Wed, 13 Jan 2021
Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day - Yahoo Finance

Mon, 11 Jan 2021
Biogen Inc. (BIIB) Rises 5.93% for January 11 -

Mon, 11 Jan 2021
Biogen Inc. (BIIB) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha

Mon, 11 Jan 2021
Biogen's stock is up 5% after Lilly reports positive data from an Alzheimer's study - MarketWatch

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 154
Shares Float (M) 153
% Held by Insiders 0.63
% Held by Institutions 87.89
Shares Short (K) 3,850
Shares Short P. Month (K) 3,710

Stock Financials

EPS 30.380
EPS Est This Year 22.100
EPS Est Next Year 23.820
Book Value (p.s.) 69.910
Profit Margin 35.63
Operating Margin 46.90
Return on Assets (ttm) 15.9
Return on Equity (ttm) 41.6
Qtrly Rev. Growth -6.2
Gross Profit (p.s.) 80.712
Sales Per Share 92.670
EBITDA (p.s.) 46.465
Qtrly Earnings Growth -54.60
Operating Cash Flow (M) 6,560
Levered Free Cash Flow (M) 4,680

Stock Valuations

PE Ratio 8.90
PEG Ratio 6.24
Price to Book value 3.87
Price to Sales 2.92
Price to Cash Flow 6.34

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.